conditional approva l of the drug, a decision that has been praised by patients as overdue and condemned by the agency's own outside experts.But both camps agree: 2030 is far too long to wait for answers on the $56,000-a-year drug."We think nine years is unacceptable and our expectation is that it will happen in a much shorter time frame," said Maria Carrillo of the Alzheimer’s Association, an advocacy group that pushed for approval but now wants the FDA to set a quicker deadline.Other experts warn that the 2030 timeline could slip if patients balk at enrolling in a new study for a drug that’s already available.